Cover Image
市場調查報告書

全球胰臟癌市場

Global Pancreatic Cancer Market 2014-2018

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 315292
出版日期 內容資訊 英文 97 Pages
訂單完成後即時交付
價格
Back to Top
全球胰臟癌市場 Global Pancreatic Cancer Market 2014-2018
出版日期: 2014年10月01日 內容資訊: 英文 97 Pages
簡介

胰臟癌的發病率、死亡率男性比女性高。美國SEER計劃(Surveillance, Epidemiology, and End Results Program),2014年推算美國有4萬6,420人的新胰臟癌案例。還有2014年美國的胰臟癌死亡數推算有3萬9,590人,這構成美國癌症死亡人數約6.8%。全球胰臟癌市場,預計從2013年到2018年,以10.70%的年複合成長率擴大。

本報告提供全球胰臟癌市場現狀與今後預測、治療類型、各地區的趨勢、市場成長要素和課題、主要企業分析等。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 簡介

第6章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第7章 市場區隔:各治療類型

  • 化療
  • 標靶治療

第8章 地區區分

  • 美國的胰臟癌市場
  • EU5個國家的胰臟癌市場

第9章 購買標準

第10章 市場成長的促進要素

第11章 促進成長要素與其影響

第12章 市場課題

第13章 促進成長要素與課題的影響

第14章 市場趨勢

第15章 趨勢與其影響

第16章 業者情勢

  • 競爭預測
  • 市場佔有率分析
  • 其他有潛力的供應商、未來的供應商

第17章 主要供應商分析

  • Celgene
    • 主要資料
    • 營業內容說明
    • 產業策略
    • 產業區分:各收益
    • 銷售額:各地區
    • 主要的發展
    • SWOT分析
  • Eli Lilly
  • F. Hoffmann-La Roche
  • Novartis
  • Pfizer

第18章 相關報告

圖表清單

目錄
Product Code: IRTNTR4314

About Pancreatic Cancer

Pancreatic cancer is a malignant cells form in the tissues of pancreas. Based on the initiation, pancreatic cancer can be classified into exocrine pancreatic cancer and endocrine pancreatic cancer. When pancreatic cancer cells spread from the pancreas to other parts of the body, it is known as metastatic pancreatic order. The incidence and mortality rate of pancreatic cancer is higher in men than in women. SEER estimates that there were 46,420 new pancreatic cancer cases recorded in the US in 2014. It also estimated that 39,590 deaths occurred in the US in 2014 as a result of pancreatic cancer, accounting for 6.8 percent of the total cancer deaths in the US.

TechNavio's analysts forecast the Global Pancreatic Cancer market to grow at a CAGR of 10.70 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Pancreatic Cancer market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of various drugs administered to treat different types of pancreatic cancer.

The report also presents the vendor landscape and a corresponding detailed analysis of the vendors in the Global Pancreatic Cancer market. In addition, it discusses the major drivers that influence the growth of the market and outlines the challenges faced by the vendors.

TechNavio's report, the Global Pancreatic Cancer market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the APAC and EMEA regions; it also covers the Global Pancreatic Cancer market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Celgene
  • Eli Lilly
  • F. Hoffmann-La Roche
  • Novartis
  • Pfizer

Other Prominent Vendors

  • AbGenomics International
  • AB Science
  • Aduro Biotech
  • Aphios
  • Celsion
  • Gilead Sciences
  • Halozyme Therapeutics
  • Merrimack Pharmaceuticals
  • Momenta Pharmaceuticals
  • OncoMed Pharmaceuticals
  • Oncozyme Pharma
  • Ostuka Holdings
  • Rexahn Pharmaceuticas
  • Zeria Pharmaceutica

Market Driver

  • Unmet Medical Need

For a full, detailed list, view our report

Market Challenge

  • High Recurrent Rates

For a full, detailed list, view our report

Market Trend

  • Use of Combination Therapies

For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2018 and what will the growth rate be
  • What are the key market trends
  • What is driving this market
  • What are the challenges to market growth
  • Who are the key vendors in this market space
  • What are the market opportunities and threats faced by the key vendors
  • What are the strengths and weaknesses of the key vendors

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
  • 06.3. Five Forces Analysis

07. Market Segmentation by Type of Therapy

  • 07.1.1. Chemotherapy
  • 07.1.2. Targeted Therapy

08. Geographical Segmentation

  • 08.1. Pancreatic Cancer Market in the US
  • 08.2. Pancreatic Cancer market in the 5EU

09. Buying Criteria

10. Market Growth Drivers

11. Drivers and their Impact

12. Market Challenges

13. Impact of Drivers and Challenges

14. Market Trends

15. Trends and their Impact

16. Vendor Landscape

  • 16.1. Competitive Scenario
    • 16.1.1. Key News
  • 16.2. Market Share Analysis 2013
  • 16.3. Other Prominent Vendors and Future Vendors

17. Key Vendor Analysis

  • 17.1. Celgene
    • 17.1.1. Key Facts
    • 17.1.2. Business Description
    • 17.1.3. Business Strategy
    • 17.1.4. Business Segmentation by Revenue 2011-2013
    • 17.1.5. Sales by Geography
    • 17.1.6. Key Developments
    • 17.1.7. SWOT Analysis
  • 17.2. Eli Lilly
    • 17.2.1. Key Facts
    • 17.2.2. Business Overview
    • 17.2.3. Business Segmentation by Revenue 2013
    • 17.2.4. Business Segmentation by Revenue 2012 and 2013
    • 17.2.5. Sales by Geography
    • 17.2.6. Business Strategy
    • 17.2.7. Key Developments
    • 17.2.8. SWOT Analysis
  • 17.3. F. Hoffmann-La Roche
    • 17.3.1. Key Facts
    • 17.3.2. Business Overview
    • 17.3.3. Business Segmentation by Revenue 2013
    • 17.3.4. Business Segmentation by Revenue 2012 and 2013
    • 17.3.5. Geographical Segmentation by Revenue 2013
    • 17.3.6. Business Strategy
    • 17.3.7. Recent Developments
    • 17.3.8. SWOT Analysis
  • 17.4. Novartis
    • 17.4.1. Key Facts
    • 17.4.2. Business Overview
    • 17.4.3. Business Segmentation by Revenue 2013
    • 17.4.4. Business Segmentation by Revenue 2012 and 2013
    • 17.4.5. Sales by Geography
    • 17.4.6. Business Strategy
    • 17.4.7. Key Developments
    • 17.4.8. SWOT Analysis
  • 17.5. Pfizer
    • 17.5.1. Key Facts
    • 17.5.2. Business Description
    • 17.5.3. Business Segmentation
    • 17.5.4. Revenue by Business Segmentation
    • 17.5.5. Revenue Comparison 2012 and 2013
    • 17.5.6. Sales by Geography
    • 17.5.7. Business Strategy
    • 17.5.8. Key Developments
    • 17.5.9. SWOT Analysis

18. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Pancreatic Cancer Market 2013-2018 (US$ million)
  • Exhibit 3: Global Pancreatic Cancer Market Segmentation by Type of Therapy
  • Exhibit 4: Global Pancreatic Cancer Market Segmentation by Geography 2013
  • Exhibit 5: Pancreatic Cancer Market in the US 2013-2018 (US$ million)
  • Exhibit 6: Pancreatic Cancer Market in the 5EU 2013-2018 (US$ million)
  • Exhibit 7: Regulatory Approval Timeline of Abraxane in the US
  • Exhibit 8: Regulatory Approval Timeline of Abraxane in the EU
  • Exhibit 9: Regulatory Approval and Revenue Trend of Abraxane
  • Exhibit 10: Quarterly Sales of Abraxane Segmented by Geography 2010-2014 (US$ million)
  • Exhibit 11: Quarterly Sales of Abraxane Segmented by Geography 2010-2014
  • Exhibit 12: Market Revenue of Abraxane 2010-2014 (US$ million)
  • Exhibit 13: Regulatory Approval Timeline of Afinitor in the US
  • Exhibit 14: Regulatory Approval Timeline of Afinitor in the EU
  • Exhibit 15: Regulatory Approval and Revenue Trend of Afinitor
  • Exhibit 16: Market Revenue of Afinitor 2008-2014 (US$ million)
  • Exhibit 17: Quarterly Sales of Afinitor 2011-2014 (US$ million)
  • Exhibit 18: Quarterly Sales of Afinitor Segmented by Geography 2012-2014 (US$ million)
  • Exhibit 19: Quarterly Sales Trend of Afinitor Segmented by Geography 2012-2014 (US$ million)
  • Exhibit 20: Regulatory Approval Timeline of Tarceva in the US
  • Exhibit 21: Regulatory Approval Timeline of Tarceva in the EU
  • Exhibit 22: Regulatory Approval and Revenue Trend of Tarceva
  • Exhibit 23: Market Revenue of Tarceva 2004-2014 (US$ million)
  • Exhibit 24: Quarterly Sales of Tarceva Segmented by Geography 2004-2008 (US$ million)
  • Exhibit 25: Quarterly Sales of Tarceva Segmented by Geography 2009-2014 (US$ million)
  • Exhibit 26: Regulatory Approval Timeline of Gemzar in the US
  • Exhibit 27: Regulatory Approval and Revenue Trend of Gemzar
  • Exhibit 28: Market Revenue of Gemzar 1996-2011 (US$ million)
  • Exhibit 29: Regulatory Approval Timeline of Sutent in the US
  • Exhibit 30: Regulatory Approval Timeline of Sutent in the EU
  • Exhibit 31: Regulatory Approval and Revenue Trend of Sutent
  • Exhibit 32: Market Revenue of Sutent 2007-2014 (US$ million)
  • Exhibit 33: Quarterly Sales of Sutent Segmented by Geography 2007-2014 (US$ million)
  • Exhibit 34: Quarterly Sales of Sutent in International Markets 2010-2014 (US$ million)
  • Exhibit 35: Celgene Corp.: Business Segmentation by Revenue 2011-2013 (US$ million)
  • Exhibit 36: Celgene Corp.: Sales by Geography 2013
  • Exhibit 37: Eli Lilly and Co.: Business Segmentation by Revenue 2013
  • Exhibit 38: Eli Lilly and Co.: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 39: Eli Lilly and Co.: Sales by Geography 2013
  • Exhibit 40: F. Hoffmann-La Roche: Business Segmentation by Revenue 2013
  • Exhibit 41: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 42: F. Hoffmann-La Roche: Geographical Segmentation by Revenue 2013 (Pharmaceuticals Division)
  • Exhibit 43: F. Hoffmann-La Roche: Geographical Segmentation by Revenue 2013 (Diagnostics Division)
  • Exhibit 44: Novartis AG: Business Segmentation by Revenue 2013
  • Exhibit 45: Novartis AG: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 46: Novartis AG: Sales by Geography 2013
  • Exhibit 47: Pfizer Inc.: Business Segmentation
  • Exhibit 48: Pfizer Inc.: Revenue by Business Segmentation 2013
  • Exhibit 49: Pfizer Inc.: Revenue by Business Segmentation 2012 and 2013
  • Exhibit 50: Pfizer Inc.: Revenue by Geography 2013
Back to Top